We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Boston, Mass.-based Global Protection has received de novo authorization from the FDA to expand the intended use claim of its ONE and myONE brand condoms to include anal sex, with the agency stressing its commitment to the needs of diverse populations. Read More
Dyad Medical’s Libby IAAA automatically does sensitive in vivo (within the heart) assessments for preclinical and clinical evaluations to optimize the design of the drug-eluting stents used to treat coronary artery disease. Read More
The company expects the diagnostic tests to be in high demand in Europe, where most of the molecular testing is performed in decentralized hospital settings. Read More